Phylogica Ltd (ASX: PYC, XETRA: PH7) has signed its fourth partnership with a major pharmaceutical company. Today, we have announced a Collaboration and Option agreement with Janssen Biotech, Inc., which is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. This partnership has the broadest scope of any of our collaborations to-date and could lead to the development of multiple Phylomer-based products.
For further information please download PDF below:
